<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756011</url>
  </required_header>
  <id_info>
    <org_study_id>Health related quality of life</org_study_id>
    <nct_id>NCT04756011</nct_id>
  </id_info>
  <brief_title>Health-related Quality of Life and Psychosocial Aspects of Diabetes Technology (Insulin Pumps)</brief_title>
  <official_title>Aspects of Diabetes Technology (Insulin Pumps) Children Perspective, a Cross - Sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be prospective comparative trial comparing between insulin pumps vs Multiple&#xD;
      daily injections (MDI) in treatment of type 1 diabetes mellitus (T1DM) in terms of health-&#xD;
      related quality of life (HRQL) and efficacy of glycemic control (HbA1c level )&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Type 1 diabetes is characterized by autoimmune destruction of insulin-secreting pancreatic b&#xD;
      cells leading to disturbed glucose regulation and overt hyperglycemia which leads to variable&#xD;
      consequences and complication. Consequently, individuals with type 1 diabetes have a lifelong&#xD;
      dependency on insulin replacement therapy.&#xD;
&#xD;
      Aim of the Work:&#xD;
&#xD;
      To compare the psychosocial impact of insulin pumps versus multiple daily injections in&#xD;
      treatment of type 1 diabetes mellitus (Via questionnaire) in terms of health-related quality&#xD;
      of life and efficacy of glycemic control (HbA1c level).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 17, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>11 Months</target_duration>
  <primary_outcome>
    <measure>Confidence in diabetes self care questionnaire (CIDS)</measure>
    <time_frame>10 min</time_frame>
    <description>the CIDS scale, assessment included HbA1c, emotional distress, fear of hypoglycemia, self-esteem, anxiety, depression, and self-care behavior. The CIDS scale is a reliable and valid measure of diabetes-specific self-efficacy for use in patients with type 1 diabetes. High psychometric similarity allows for cross-cultural comparisons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>socioeconomic level of the family scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>Assessment of family socioeconomic standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MINI-KID (Mini International Neuropsychiatric Interview )</measure>
    <time_frame>25 minutes</time_frame>
    <description>Mini International Neuropsychiatric Interview for Children and Adolescents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of health-related quality of life (HRQL)</measure>
    <time_frame>5 minutes</time_frame>
    <description>HRQL was measured by the Peds-QL 4.0 11,22. The 23-item Peds-QL 4.0 generic core scales encompass (a) physical functioning (eight items), (b) emotional functioning (five items), (c) social functioning (five items), and (d) school functioning (five items). The physical health summary score (eight items) is the same as the physical functioning scale. To create the psychosocial health summary score (15 items), the mean is computed as the sum of the items divided by the number of items answered in the emotional, social, and school functioning scales.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>T1DM</condition>
  <condition>Health Related Quality of Life</condition>
  <condition>Insulin Pump</condition>
  <arm_group>
    <arm_group_label>Group A (insulin pump)</arm_group_label>
    <description>30 patients who are on insulin pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (MDI)</arm_group_label>
    <description>30 patients who are on multiple daily injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Health related quality of life</intervention_name>
    <description>Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL</description>
    <arm_group_label>Group A (insulin pump)</arm_group_label>
    <arm_group_label>Group B (MDI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Ain shams pediatric and adolescent diabetes unit(PADU)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Type 1 diabetes mellitus.&#xD;
&#xD;
          -  2.Patients who are on insulin pumps must be for at least 3 months on them&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Other types of DM e.g., T2DM, MODY.&#xD;
&#xD;
          -  2. Patients with other comorbidities; cardiac, renal, neurological, hepatic â€¦.etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abbasia</state>
        <zip>11517</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin pump</keyword>
  <keyword>T1DM</keyword>
  <keyword>HRQL</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

